Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine

The Journal of Headache and Pain

Rapid Communication

Giovanna Gentile¹  Serena Missori²  Noemi Lala²  Paolo Martelletti²  Marina Borro³  Maurizio Simmaco³ 

[1] Department of Biochemical Sciences, Advanced Molecular Diagnostic Unit, 2nd School of Medicine, Sant’Andrea Hospital, Sapienza University of Rome, Via di Grottarossa 1035, 00189, Rome, Italy;Department of Medical and Molecular Sciences, Regional Referral Headache Center, 2nd School of Medicine, Sant’Andrea Hospital, Sapienza University of Rome, Via di Grottarossa 1035, 00189, Rome, Italy;NESMOS Department, Advanced Molecular Diagnostic Unit, 2nd School of Medicine, Sant’Andrea Hospital, Sapienza University of Rome, Via di Grottarossa 1035, 00189, Rome, Italy;

关键词: Chronic migraine;    SNPs;    Triptan overuse;    Triptan efficacy;    Polymorphisms;   

DOI  :  10.1007/s10194-010-0241-0

 received in 2010-04-23, accepted in 2010-07-02,  发布年份 2010

来源: Springer

【 摘 要 】

Migraine is a common type of headache and its most severe attacks are usually treated with triptans, the efficacy of which is extremely variable. Several SNPs in genes involved in metabolism and target mechanisms of triptans have been described. To define an association between genetic profile and triptan response, we classified a migrainous population on the basis of triptan response and characterized it for polymorphisms in the genes coding for monoamine oxidase A, G protein β3 and the cytochrome CYP1A2. Analysis of the association between genotypic and allelic frequencies of the analyzed SNPs and the grade of response to triptan administration showed a significant correlation for MAOA uVNTR polymorphism. Further stratification of patients in abuser and non-abuser groups revealed a significant association with triptan overuse and, within the abusers, with drug response to the CYP1A2*1F variant.

【 授权许可】

Unknown   
© Springer-Verlag 2010